Top

Acta Diabetologica

Published in:

Open Access 01-08-2019 | Albuminuria | Review Article

Association of smoking and cardiometabolic parameters with albuminuria in people with type 2 diabetes mellitus: a systematic review and meta-analysis

Authors: Debasish Kar, Clare Gillies, Mintu Nath, Kamlesh Khunti, Melanie J. Davies, Samuel Seidu

Published in: Acta Diabetologica | Issue 8/2019

Abstract

Aims

Smoking is a strong risk factor for albuminuria in people with type 2 diabetes mellitus (T2DM). However, it is unclear whether this sequela of smoking is brought about by its action on cardiometabolic parameters or the relationship is independent. The aim of this systematic review is to explore this relationship.

Methods

Electronic databases on cross-sectional and prospective studies in Medline and Embase were searched from January 1946 to May 2018. Adult smokers with T2DM were included, and other types of diabetes were excluded.

Results

A random effects meta-analysis of 20,056 participants from 13 studies found that the odds ratio (OR) of smokers developing albuminuria compared to non-smokers was 2.13 (95% CI 1.32, 3.45). Apart from smoking, the odds ratio of other risk factors associated with albuminuria were: age 1.24 (95% CI 0.84, 1.64), male sex 1.39 (95% CI 1.16, 1.67), duration of diabetes 1.78 (95% CI 1.32, 2.23), HbA1c 0.63 (95% CI 0.45, 0.81), SBP 6.03 (95% CI 4.10, 7.97), DBP 1.85 (95% CI 1.08, 2.62), total cholesterol 0.06 (95% CI − 0.05, 0.17) and HDL cholesterol − 0.01 (95% CI − 0.04, 0.02), triglyceride 0.22 (95% CI 0.12, 0.33) and BMI 0.40 (95% CI 0.00–0.80). When the smoking status was adjusted in a mixed effect meta-regression model, the duration of diabetes was the only statistically significant factor that influenced the prevalence of albuminuria. In smokers, each year’s increase in the duration of T2DM was associated with an increased risk of albuminuria of 0.19 units (95% CI 0.07, 0.31) on the log odds scale or increased the odds approximately by 23%, compared to non-smokers. Prediction from the meta-regression model also suggested that the odds ratios of albuminuria in smokers after a diabetes duration of 9 years and 16 years were 1.53 (95% CI 1.10, 2.13) and 5.94 (95% CI 2.53, 13.95), respectively.

Conclusions

Continuing to smoke and the duration of diabetes are two strong predictors of albuminuria in smokers with T2DM. With a global surge in younger smokers developing T2DM, smoking cessation interventions at an early stage of disease trajectory should be promoted.

Available only for authorised users

Pan A, Wang Y, Talaei M, Hu FB (2015) Relation of smoking with total mortality and cardiovascular events among patients with diabetes mellitus: a meta-analysis and systematic review. Circulation 132(19):1795–1804PubMedPubMedCentralCrossRef

Kar D, Gillies C, Zaccardi F, Webb D, Seidu S, Davies M et al (2016) Relationship of cardiometabolic parameters in non-smokers, current smokers, and quitters in diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol 15:158PubMedPubMedCentralCrossRef

Clair C, Rigotti NA, Porneala B, Fox CS, D’Agostino RB, Pencina MJ et al (2013) Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA 309(10):1014–1021PubMedPubMedCentralCrossRef

Chaturvedi N, Stevens L, Fuller JH (1997) Which features of smoking determine mortality risk in former cigarette smokers with diabetes? The World Health Organization Multinational Study Group. Diabetes care 20(8):1266–1272PubMedCrossRef

Eijkelkamp WB, Zhang Z, Brenner BM, Cooper ME, Devereux RB, Dahlof B et al (2007) Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. J Hypertens 25:876CrossRef

Lee ET, Howard BV, Wang W, Welty TK, Galloway JM, Best LG et al (2006) Prediction of coronary heart disease in a population with high prevalence of diabetes and albuminuria: the Strong Heart Study. Circulation 113(25):2897–2905PubMedCrossRef

Singh DK, Winocour P, Summerhayes B, Sivakumar G, Viljoen A, Farrington K (2009) The relationship of albuminuria and vascular calcification in type 2 diabetes. Diabetes 58(1):A198

Di Landro D, Catalano C, Lambertini D, Bordin V, Fabbian F, Naso A et al (1998) The effect of metabolic control on development and progression of diabetic nephropathy. Nephrol Dial Transplant 13(Suppl 8):35–43PubMedCrossRef

Ascic-Buturovic B, Kacila M, Kulic M (2009) Effects of aggressive approach to the multiple risk factors for diabetic nephro-pathy on proteinuria reduction in diabetes type 2 patients. Bosn J Basic Med Sci 9(1):44–48PubMedPubMedCentralCrossRef

10.

Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: elaboration and explanation. BMJ (Online) 349:1

11.

Miller W, Bruns D, Hortin G, Sandberg S, Aakre K, McQueen M et al (2009) Current issues in measurement and reporting of urinary albumin excretion. Clin Chem 55(1):24–38PubMedCrossRef

12.

Stang A (2010) Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605PubMedCrossRef

13.

Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558PubMedCrossRef

14.

Chase HP, Garg SK, Marshall G, Berg CL, Harris S, Jackson WE et al (1991) Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. JAMA 265(5):614–617PubMedCrossRef

15.

Amin R, Widmer B, Prevost AT, Schwarze P, Cooper J, Edge J et al (2008) Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: prospective observational study. BMJ 336(7646):697–701PubMedPubMedCentralCrossRef

16.

Abuaisha B, Kumar S, Malik R, Boulton AJ (1998) Relationship of elevated urinary albumin excretion to components of the metabolic syndrome in non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 39(2):93–99PubMedCrossRef

17.

Temimovic R, Rasic S (2015) Impact of obesity and smoking on the values of albuminuria and proteinuria in high risk patients and its impact on development of early chronic kidney disease in outpatients in bosnia herzegovina. Nephrol Dial Transplant 30:iii489CrossRef

18.

Christiansen JS (1978) Cigarette smoking and prevalence of microangiopathy in juvenile-onset insulin-dependent diabetes mellitus. Diabetes care 1(3):146PubMedCrossRef

19.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes care 38(1):140–149PubMedCrossRef

20.

Boger CA, Haak T, Gotz AK, Christ J, Ruff E, Hoffmann U et al (2006) Effect of ACE and AT-2 inhibitors on mortality and progression to microalbuminuria in a nested case-control study of diabetic nephropathy in diabetes mellitus type 2: results from the GENDIAN study. Int J Clin Pharmacol Ther 44:364–74PubMedCrossRef

21.

Yamashita T, Makino H, Nakatani R, Ohata Y, Miyamoto Y, Kishimoto I (2013) Renal insufficiency without albuminuria is associated with peripheral artery atherosclerosis and lipid metabolism disorders in patients with type 2 diabetes. J Atheroscler Thromb 20(11):790–797PubMedCrossRef

22.

Wall BM, Hardison RM, Molitch ME, Marroquin OC, McGill JB, August PA (2010) High prevalence and diversity of kidney dysfunction in patients with type 2 diabetes mellitus and coronary artery disease: the BARI 2D baseline data. Am J Med Sci 339:401–10PubMedPubMedCentralCrossRef

23.

24.

Chuahirun T, Wesson DE (2002) Cigarette smoking predicts faster progression of type 2 established diabetic nephropathy despite ACE inhibition. Am J Kidney Dis 39(2):376–382PubMedCrossRef

25.

de Boer IH, Astor BC, Kramer H, Palmas W, Seliger SL, Shlipak MG et al (2008) Lipoprotein abnormalities associated with mild impairment of kidney function in the multi-ethnic study of atherosclerosis. Clin J Am Soc Nephrol CJASN 3(1):125–132PubMedCrossRef

26.

Berlin I (2008) Smoking-induced metabolic disorders: a review. Diabetes Metab 34(4 Pt 1):307–314PubMedCrossRef

27.

Freeman DJ, Caslake MJ, Griffin BA, Hinnie J, Tan CE, Watson TD et al (1998) The effect of smoking on post-heparin lipoprotein and hepatic lipase, cholesteryl ester transfer protein and lecithin:cholesterol acyl transferase activities in human plasma. Eur J Clin Investig 28(7):584CrossRef

28.

Zong C, Song G, Yao S, Guo S, Yu Y, Yang N et al (2015) Cigarette smoke exposure impairs reverse cholesterol transport which can be minimized by treatment of hydrogen- saturated saline. Lipids Health Dis 14(1):159-PubMedPubMedCentralCrossRef

29.

Campbell SC, Moffatt RJ, Stamford BA (2008) Smoking and smoking cessation—the relationship between cardiovascular disease and lipoprotein metabolism: a review. Atherosclerosis 201(2):225–235CrossRef

30.

Ferrara CM, Kumar M, Nicklas B, McCrone S, Goldberg AP (2001) Weight gain and adipose tissue metabolism after smoking cessation in women. Int J Obes 25(9):1322–1326CrossRef

31.

Zoppini G, Targher G, Chonchol M, Perrone F, Lippi G, Muggeo M (2009) Higher HDL cholesterol levels are associated with a lower incidence of chronic kidney disease in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis 19:580–6PubMedCrossRef

32.

Sawicki PT, Muhlhauser I, Bender R, Pethke W, Heinemann L, Berger M (1996) Effects of smoking on blood pressure and proteinuria in patients with diabetic nephropathy. J Intern Med 239(4):345–352PubMedCrossRef

33.

Orth SR (2004) Effects of smoking on systemic and intrarenal hemodynamics: influence on renal function. J Am Soc Nephrol 15(Suppl 1):58CrossRef

34.

Ritz E, Ogata H, Orth SR (2000) Smoking: a factor promoting onset and progression of diabetic nephropathy. Diabetes Metab 26(Suppl 4):54–63PubMed

35.

Orth SR, Schroeder T, Ritz E, Ferrari P (2005) Effects of smoking on renal function in patients with type 1 and type 2 diabetes mellitus. Nephrol Dial Transplant 20(11):2414–2419PubMedCrossRef

36.

Orth SR (2002) Cigarette smoking: an important renal risk factor—far beyond carcinogenesis. Tob Induc Dis 1(2):137–155PubMedPubMedCentralCrossRef

37.

Baggio B, Budakovic A, Dalla Vestra M, Saller A, Bruseghin M, Fioretto P (2002) Effects of cigarette smoking on glomerular structure and function in type 2 diabetic patients. J Am Soc Nephrol 13(11):2730–2736PubMedCrossRef

38.

Agarwal R (2005) Smoking, oxidative stress and inflammation: impact on resting energy expenditure in diabetic nephropathy. BMC Nephrol 6:13PubMedPubMedCentralCrossRef

39.

Canoy D, Wareham N, Luben R, Welch A, Bingham S, Day N et al (2005) Cigarette smoking and fat distribution in 21,828 british men and women: a population-based study. Obesity 13(8):1466–1475CrossRef

40.

Axelsson T, Jansson PA, Smith U, Eliasson B, Sahlgrenska a, Institutionen för i et al (2001) Nicotine infusion acutely impairs insulin sensitivity in type 2 diabetic patients but not in healthy subjects. J Intern Med 249(6):539–544PubMedCrossRef

41.

Kim JH, Shim KW, Yoon YS, Lee SY, Kim SS, Oh SW (2012) Cigarette smoking increases abdominal and visceral obesity but not overall fatness: an observational study. PLoS One 7(9):e45815PubMedPubMedCentralCrossRef

42.

Clair C, Rigotti N, Shrader P, Caroline P, Pencina M, Meigs J (2011) Effects of smoking, cessation and weight change on cardiovascular disease among people with and without diabetes. J Gen Intern Med 26:S12–S14CrossRef

43.

Gerstein HC, Mann JF, Pogue J, Dinneen SF, Halle JP, Hoogwerf B et al (2000) Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. Diabetes Care 23(Suppl 2):35

44.

Organization WH (2016) Global report on diabetes

45.

Savage S, Estacio RO, Jeffers B, Schrier RW (1996) Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM. Diabetes care 19(11):1243–1248CrossRef

46.

Constantino M, Molyneaux L, Gisler F, Al Saeed A, Luo C, Wu T et al (2012) Long term complications and mortality in youth onset diabetes: type 2 diabetes is more lethal than type 1 diabetes. Diabetes Care 61(s1):A88-A

47.

Group TS (2013) Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care 36(6):1735–1741CrossRef

48.

Whiting DR, Guariguata L, Weil C, Shaw J (2011) IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94(3):311–321PubMedCrossRef

49.

Dabelea D, Department of Epidemiology CSoPH, Aurora, Stafford JM, Department of Biostatistical Sciences WFSoM, Winston-Salem, North Carolina, Mayer-Davis EJ, Departments of Nutrition and Medicine UoNC, Chapel Hill et al (2017) Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood. JAMA 317(8):825–835PubMedPubMedCentralCrossRef

50.

Chuahirun T, Khanna A, Kimball K, Wesson DE (2003) Cigarette smoking and increased urine albumin excretion are interrelated predictors of nephropathy progression in type 2 diabetes. Am J Kidney Dis 41:13–21PubMedCrossRef

51.

Chuahirun T, Simoni J, Hudson C, Seipel T, Khanna A, Harrist RB et al (2004) Cigarette smoking exacerbates and its cessation ameliorates renal injury in type 2 diabetes. Am J Med Sci 327(2):57–67PubMedCrossRef

52.

Ikeda Y, Suehiro T, Takamatsu K, Hashimoto K, Yamashita H, Tamura T (1997) Effect of smoking on the prevalence of albuminuria in Japanese men with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 36(1):57–61PubMedCrossRef

53.

Tseng CH, Tseng CP, Chong CK. Joint effects of hypertension, smoking, dyslipidemia and obesity and angiotensin-converting enzyme DD genotype on albuminuria in Taiwanese patients with type 2 diabetes mellitus. Clin Biochem 2010;43:629–34PubMedCrossRef

54.

Voulgari C, Katsilambros N, Tentolouris N (2011) Smoking cessation predicts amelioration of microalbuminuria in newly diagnosed type 2 diabetes mellitus: a 1-year prospective study. Metabolism 60:1456–64PubMedCrossRef

55.

Phisitkul K, Hegazy K, Chuahirun T, Hudson C, Simoni J, Rajab H et al (2008) Continued smoking exacerbates but cessation ameliorates progression of early type 2 diabetic nephropathy. Am J Med Sci 335:284–91PubMedCrossRef

56.

Hsu CC, Hwang SJ, Tai TY, Chen T, Huang MC, Shin SJ et al (2010) Cigarette smoking and proteinuria in Taiwanese men with type 2 diabetes mellitus. Diabet Med 27(3):295–302PubMedCrossRef

57.

Cederholm J, Eliasson B, Nilsson PM, Weiss L, Gudbjörnsdottir S (2005) Microalbuminuria and risk factors in type 1 and type 2 diabetic patients. Diabetes Res Clin Pract 67(3):258–266PubMedCrossRef

58.

Savage S, Nagel NJ, Estacio RO, Lukken N, Schrier RW. Clinical factors associated with urinary albumin excretion in type II diabetes. Am J Kidney Dis 1995;25:836–44PubMedCrossRef

59.

Ohkuma T, Nakamura U, Iwase M, Ide H, Fujii H, Jodai T et al (2016) Effects of smoking and its cessation on creatinine- and cystatin C-based estimated glomerular filtration rates and albuminuria in male patients with type 2 diabetes mellitus: the Fukuoka Diabetes Registry. Hypertens Res 39(10):744–751PubMedCrossRef

60.

Prashanth P, Sulaiman KJ, Kadaha G, Bazarjani N, Bakir S, Jabri KE et al (2010) Prevalence and risk factors for albuminuria among type 2 diabetes mellitus patients: a middle-east perspective. Diabetes Res Clin Pract 88(3):e24–e27PubMedCrossRef

61.

Corradi L, Zoppi A, Tettamanti F, Malamani G, Lazzari P, Fogari R (1993) Association between smoking and micro-albuminuria in hypertensive patients with type 2 diabetes mellitus. J Hypertens 11:S190-1CrossRef

62.

Anan F, Nakagawa M, Yonemochi H, Saikawa T, Masaki T, Takahashi N et al (2007) Smoking is associated with urinary albumin excretion: an evaluation of premenopausal patients with type 2 diabetes mellitus. Metab Clin Exp 56(2):179–184PubMedCrossRef

63.

Hyungseon Y, Jung Hyun L, Hyeon Chang K, Il S (2016) The association between smoking tobacco after a diagnosis of diabetes and the prevalence of diabetic nephropathy in the korean male population. J Prev Med Public Health 49(2):108–117CrossRef

64.

Forsblom CM, Totterman KJ, Saloranta C, Groop PH, Ekstrand A, Sane T et al (1998) Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM. Diabetes Care 21(11):1932–1938PubMedCrossRef

65.

Thomas GN, Tomlinson B, McGhee SM, Lam TH, Abdullah ASM, Yeung VTF et al (2006) Association of smoking with increasing vascular involvement in type 2 diabetic chinese patients. Exp Clin Endocrinol Diabetes 114(06):301–305PubMedCrossRef

66.

Kanauchi M, Kawano T, Akai M, Yashima I, Nishioka H, Nakashima Y et al (1998) Smoking habit and progression of diabetic nephropathy. J Nara Med Assoc 49(2):85–89

67.

Gambaro G, Bax G, Fusaro M, Normanno M, Manani SM, Zanella M et al (2001) Cigarette smoking is a risk factor for nephropathy and its progression in type 2 diabetes mellitus. Diabetes Nutr Metab Clin Exp 14(6):337–342

68.

West KM, Erdreich LS, Stober JA (1980) Absence of a relationship between smoking and diabetic microangiopathy. Diabetes care 3(2):250–252PubMedCrossRef

69.

Klein R, Klein BE, Moss SE (1993) Incidence of gross proteinuria in older- onset diabetes. A population- based perspective. Diabetes 42(3):381PubMedCrossRef

70.

Bruno G, Cavallo-Perin P, Bargero G, Borra M, Calvi V, D’Errico N et al (1996) Prevalence and risk factors for micro- and macroalbuminuria in an Italian population-based cohort of NIDDM subjects. Diabetes Care 19(1):43–47PubMedCrossRef

71.

Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Pagano G et al (2003) Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 26(7):2150–2155PubMedCrossRef

72.

Bentata Y, Karimi I, Benabdellah N, El Alaoui F, Haddiya I, Abouqal R (2016) Does smoking increase the risk of progression of nephropathy and/or cardiovascular disease in type 2 diabetic patients with albuminuria and those without albuminuria? Am J Cardiovasc Dis 6(2):66–69PubMedPubMedCentral

73.

Kohler KA, McClellan WM, Ziemer DC, Kleinbaum DG, Boring JR (2000) Risk factors for microalbuminuria in black americans with newly diagnosed type 2 diabetes. Am J Kidney Dis 36(5):903–913PubMedCrossRef

74.

Nilsson P, Gudbjörnsdottir S, Eliasson B, Cederholm J (2004) Smoking is associated with increased HbA 1c values and microalbuminuria in patients with diabetes—data from the National Diabetes Register in Sweden. Diabetes Metab 30(3):261–268PubMedCrossRef

75.

Pijls LT, de Vries H, Kriegsman DM, Donker AJ, van Eijk JT (2001) Determinants of albuminuria in people with type 2 diabetes mellitus. Diabetes Res Clin Pract 52(2):133–143PubMedCrossRef

76.

Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG, DEMAND investigators (2006) Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 69(11):2057–2063PubMedCrossRef

Title: Association of smoking and cardiometabolic parameters with albuminuria in people with type 2 diabetes mellitus: a systematic review and meta-analysis
Authors: Debasish Kar
Clare Gillies
Mintu Nath
Kamlesh Khunti
Melanie J. Davies
Samuel Seidu
Publication date: 01-08-2019
Publisher: Springer Milan
Keywords: Albuminuria
Diabetes
Type 2 Diabetes
Published in: Acta Diabetologica / Issue 8/2019
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-019-01293-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Association of smoking and cardiometabolic parameters with albuminuria in people with type 2 diabetes mellitus: a systematic review and meta-analysis

Abstract

Aims

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Aims

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2019

Functional characterization of p.Pro409His variant in HNF1A, a hypomorphic mutation involved in pancreatic β-cell dysfunction

Physical activity and risk of diabetic retinopathy: a systematic review and meta-analysis

FreeStyle Libre flash glucose monitoring system in pregnant woman with type 1 diabetes: a focus on accuracy

Serum levels of immunoglobulin G and complement 3 differentiate non-diabetic renal disease from diabetic nephropathy in patients with type 2 diabetes mellitus

Correction to: Dietary protein intake and subsequent risk of type 2 diabetes: a dose–response meta-analysis of prospective cohort studies

Clinical inertia in insulin initiation in type 2 diabetes across Central and Southeastern Europe

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page